A 81-year-old man was admitted to our department with the chief complaints of pollakisuria and difficulty in voiding. He presented with increased serum PSA level (over 100 ng/ml). We performed biopsy of the prostate and found a moderately differentiated adenocarcinoma. Various urological examinations showed metastases to paraaortic lymph nodes and systemic bones. He was started-on hormonal therapy. Nine months from the start of hormonal therapy, this therapy was effective and the serum PSA level was decreased to 14 ng/ml. Thereafter, the serum PSA level and the tumor volume were increased and he died 29 months from the start of treatment. The autopsy revealed small cell carcinoma with adenocarcinoma of the prostate.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Relationship Between Pre- and Post-Orchidectomy Serum Dihydrotestosterone and Prostate Cancer Severity in a Cohort of Nigerian Patients.
West Afr J Med
September 2024
Urology Department, Dorset County Hospital, Dorchester, UK.
Introduction: Prostate cancer (PCa) is the commonest urologic cancer worldwide and the leading cause of male cancer deaths in Nigeria. In Nigeria, orchidectomy remains the primary androgen deprivation therapy. Dihydrotestosterone (DHT) is the active prostatic androgen, but its relationship with PCa severity has not been extensively studied in Africa.
View Article and Find Full Text PDF"Utility of PET/CT with [F] F-fluorocholine in assessing the response to antiandrogenic therapy in patients with prostate cancer.".
Rev Esp Med Nucl Imagen Mol (Engl Ed)
January 2025
Servicio de Medicina Nuclear, Hospital Clínic Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) y Universitat de Barcelona (UB), Barcelona, Spain.
Objective: To evaluate the correlation between response assessment measured by PET/CT with [F] F-fluorocholine (Choline PET/CT) and serum levels of PSA in patients with prostate cancer under antiandrogenic treatment.
Methodology: A retrospective study included patients with CRPC and CSPC treated with enzalutamide, abiraterone, or apalutamide between June 2018 and July 2021, who underwent baseline and a follow-up Choline PET/CT. The difference in maximum SUVmax (ΔSUV) between both studies and the PSA value before and at follow-up were recorded.
CIRCULATING miR-1-3p, miR-96-5p, miR-148a-3p, and miR-375-3p Support Differentiation Between Prostate Cancer and Benign Prostate Lesions.
Clin Genitourin Cancer
December 2024
Department of Urology, Centre of Postgraduate Medical Education, Independent Public Hospital of Prof. W. Orlowski, Warsaw, Poland.
Introduction: microRNAs (miRNAs) are small noncoding RNAs and promising cancer biomarkers. Prostate-specific antigen (PSA) testing revolutionized prostate cancer (PCa) diagnostics and monitoring. However, PSA testing also contributes to PCa overdiagnoses that are detrimental on patients' health and may lead to overtreatment.
View Article and Find Full Text PDFElectrochemical immunosensor for PA toxin using a polypyrrole-gold nanoparticle/multiwall carbon nanotube sensing platform and cadmium sulphide nanocrystal signal tag.
Anal Methods
January 2025
Defence Research and Development Establishment, Jhansi Road, Gwalior, Madhya Pradesh 474002, India.
A sandwich electrochemical immunosensor was proposed for the sensitive detection of protective antigen ( PA) toxin based on cadmium sulphide nanocrystals (CdS NCs) and polypyrrole-gold nanoparticle-modified multiwalled carbon nanotubes (PPy-AuNPs/MWCNTs). Herein, PPy-AuNPs/MWCNTs were used as a biocompatible and conducting matrix for immobilization of rabbit anti-PA antibody [RαPA antibody, capturing antibody (Ab1)] and to facilitate excellent electrical conductivity. PPy-AuNPs/MWCNTs were synthesized through a one-step chemical reaction of pyrrole and Au on the surface of MWCNTs.
View Article and Find Full Text PDFExploring the potential of as a diagnostic biomarker in prostate cancer.
Urologia
January 2025
Department of Urology, IPGMER and SSKM Hospital, Kolkata, West Bengal, India.
Background: Exploring the potential of as a diagnostic biomarker in prostate cancer.
Methods: Expression of the lncRNA was analyzed between normal and tumor samples in the GDC TCGA PRAD (Genomic Data Commons: The Cancer Genome Atlas Prostate Adenocarcinoma Collection) dataset. Disease progression-related clinicopathological parameters such as serum PSA level (ng/ml) and Gleason score were associated with the expression of using the same GDC TCGA PRAD dataset.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!